Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 8/20 | 0.44 |
| ▸ | DRD4 | P21917 | 6/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | EPHB3 | P54753 | 3/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9607549 | 0.85 | SSTR4 (0.48) | SSTR4DRD3DRD4DYRK1AEPHB3 | |
| SCHEMBL16256035 | 0.82 | SSTR4 (0.46) | SSTR4DRD3DRD4DYRK1AEPHB3 | |
| SCHEMBL21451299 | 0.79 | SSTR4 (0.44) | SSTR4DRD3DRD4DYRK1AEPHB3 | |
| SCHEMBL18074412 | 0.78 | SSTR4 (0.46) | SSTR4DRD3DRD4EPHB3JAK2 | |
| SCHEMBL28885874 | 0.75 | SSTR4 (0.47) | SSTR4EPHB3JAK2JAK1TYK2 | |
| SCHEMBL28885872 | 0.75 | SSTR4 (0.47) | SSTR4EPHB3JAK2JAK1TYK2 | |
| SCHEMBL22360678 | 0.72 | SSTR4 (0.42) | SSTR4DRD3DRD4DYRK1AEPHB3 | |
| SCHEMBL19901794 | 0.71 | SSTR4 (0.41) | SSTR4DRD3DRD4DYRK1AEPHB3 | |
| SCHEMBL33601 | 0.71 | SMPD3 (0.47) | DRD3DRD4DYRK1AEPHB3CCNK | |
| SCHEMBL84746 | 0.71 | NPC1 (0.47) | DRD3DRD4DYRK1AEPHB3CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-10675268-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190269650-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2019-09-05 | — | — | US | disclosed |
| US-10166214-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2018-04-05 | — | — | US | disclosed |
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2018-04-05 | — | — | US | disclosed |
| EP-2997021-B1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | CENTREXION THERAPEUTICS CORP (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9789082-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789082-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-9371282-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371282-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR3, SSTR1 | SSTR4 1/4885DRD3 848/4885DRD4 502/4885 |
| US-20190269650-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR3, SSTR1 | SSTR4 1/4885DRD3 641/4885DRD4 428/4885 |
| US-10675268-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR1 | SSTR4 1/4885DRD3 848/4885DRD4 502/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | SSTR4 2673/4885DRD3 1018/4885DRD4 1861/4885 |
| US-10166214-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR1 | SSTR4 1/4885DRD3 848/4885DRD4 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.